stockrow
Friday 6 November 2026
Export HRMY’s income statement to Excel — free account
Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
33.04
0.57
+1.76%
Follow HRMY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
13.61 | 11.12 | 11.63 | 12.77 |
P/S ratio |
2.48 | 1.80 | 2.20 | 2.32 | |
P/FCF ratio |
6.99 | 5.37 | 6.70 | 8.11 | |
P/Operating CF |
17.05 | 58.34 | 22.82 | 29.90 | |
P/B ratio |
2.47 | 1.78 | 2.11 | 2.14 | |
Price to Tangible BV |
2.76 | 1.96 | 2.29 | 2.29 | |
EV/Sales |
1.77 | 1.27 | 1.66 | 1.69 | |
EV/EBITDA |
6.61 | 5.31 | 6.25 | 6.86 | |
EV/Operating CF |
4.42 | 3.33 | 4.49 | 5.17 | |
EV/FCF |
5.00 | 3.77 | 5.07 | 5.91 | |
Quick Ratio |
3.46 | 3.45 | 3.33 | 3.31 | |
Current Ratio |
3.60 | 3.58 | 3.48 | 3.44 | |
Net Debt/EBITDA |
(13.34) | (11.16) | (5.41) | (10.44) | |
Debt/Assets |
12.87% | 12.49% | 11.21% | 10.09% | |
Debt/Equity |
0.19 | 0.17 | 0.15 | 0.14 | |
Asset Turnover |
0.76 | 0.77 | 0.77 | 0.74 | |
Operating CF/Net income |
5.61 | 0.85 | 1.23 | 1.59 | |
Capex/Depreciation |
(0.01) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
10.87 | 11.53 | 29.09 | 17.71 | |
Research and Development Expense of Revenue |
20.48% | 32.21% | 17.83% | 26.65% | |
Selling, General and Administrative Expense of Revenue |
35.58% | 29.81% | 23.79% | 23.19% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
4.09% | 4.93% | 3.57% | 2.99% | |
Graham Net Nets |
0.24 | 0.26 | 0.21 | 0.23 | |
Graham Number |
30.60 | 29.88 | 34.85 | 35.64 | |
Earnings Yield |
7.35% | 9.00% | 8.60% | 7.83% | |
Free Cash Flow Yield |
14.31% | 18.63% | 14.92% | 12.33% | |
Revenue per Share |
4.24 | 3.73 | 4.51 | 4.60 | |
Operating CF per Share |
2.19 | 0.48 | 1.60 | 1.31 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
2.19 | 0.48 | 1.60 | 1.31 | |
Cash per Share |
13.49 | 11.08 | 11.53 | 13.20 | |
Shareholders Equity per Share |
15.14 | 15.74 | 17.25 | 18.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.14 | 15.74 | 17.25 | 18.36 | |
Free Cash Flow |
126.04 | 27.76 | 92.43 | 76.69 | |
Working Capital |
654.88 | 561.48 | 580.26 | 663.29 | |
Capital Expenditures |
(0.11) | — | — | — | |
Net Current Asset Value |
505.60 | 417.34 | 440.49 | 528.82 | |
EV/EBIT |
7.39 | 6.00 | 6.92 | 7.62 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
10.32 | 8.55 | 9.15 | 10.45 | |
| Other line items | |||||
Average Receivables |
89.91 | 107.10 | 101.99 | 114.20 | |
Average Payables |
15.72 | 23.03 | 24.99 | 26.63 | |
Average Inventory |
6.28 | 5.83 | 6.23 | 6.38 | |
Average Assets |
1,135.42 | 1,163.68 | 1,240.55 | 1,343.23 | |
Average Common Equity |
764.69 | 815.44 | 886.16 | 953.68 |
Columns are period end dates · fundamentals updated 6 Nov 2026